Price Volatility is mainly due to the Fundamental Analysis. Not a lot to say on Technical Analysis
Vaxart Inc. VXRT, +28.43% said Friday its oral COVID-19 vaccine has been selected to take part in a nonhuman primate challenge study funded by the U.S. government’s ‘Operation Warp Speed’ program, that aims to accelerate development of a vaccine. Shares were up more than 28%.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.